| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8078f9ef0ce6eb4affce2bc6ae52e391 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 |
| filingDate |
1999-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aab634f4d6c2820b52cd5284ef67c2a0 |
| publicationDate |
2001-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20010018158-A |
| titleOfInvention |
The nasal transmucosal delivery of peptides conjugated with biocompatible polymers |
| abstract |
The present invention relates to a pharmaceutical composition for non-mucosa modified with a biocompatible polymer to the peptide, more specifically to modifying the polyethylene glycol (PEG) activated to a biologically active peptide (peptide) to increase the solubility of poorly soluble peptides It increases the stability by preventing degradation by the enzyme in the body, and by delivering the peptide-polymer conjugate to the nasal cavity, as well as the rapid expression of the action of the drug can improve the bioavailability, by modifying the biocompatible polymer to the peptide It relates to a pharmaceutical composition for nasal mucosal delivery. |
| priorityDate |
1999-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |